BSE Live
Prev. Close
Open Price
Bid Price (Qty.)
()
Offer Price (Qty.)
()
NSE Live
Apr 20, 15:47Prev. Close
1375.50
Open Price
1400.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of Beta Drugs (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 25.41 | 29.48 | 25.21 | 20.16 | 9.88 | |
| Net CashFlow From Operating Activities | 18.04 | 21.19 | 10.23 | 18.76 | 11.60 | |
| Net Cash Used In Investing Activities | -21.46 | -11.02 | -5.82 | -12.72 | -3.15 | |
| Net Cash Used From Financing Activities | 118.20 | -0.76 | -2.19 | 1.27 | -4.34 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 114.79 | 9.40 | 2.21 | 7.31 | 4.10 | |
| Cash And Cash Equivalents Begin of Year | 27.20 | 17.79 | 15.58 | 8.27 | 4.16 | |
| Cash And Cash Equivalents End Of Year | 141.99 | 27.20 | 17.79 | 15.58 | 8.27 |
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth